Arthur Levin
Director/Board Member bij AVIDITY BIOSCIENCES, INC.
Vermogen: 7 M $ op 31-03-2024
Profiel
Arthur A.
Levin is currently the Director & Strategic Leader at Avidity Biosciences, Inc., an Independent Director at Stoke Therapeutics, Inc., and a Member-Supervisory Board at Amylon Therapeutics BV.
Previously, he served as a Director at Oligonucleotide Therapeutics Society, Inc., Senior Vice President-Development at Ionis Pharmaceuticals, Inc., Executive Vice President-Research & Development at miRagen Therapeutics, Inc., Research Leader at Hoffmann-La Roche, Inc., and Chief Development Officer & Vice President at Roche Innovation Center Copenhagen A.
Dr. Levin holds a doctorate degree from Rochester Christian University and an undergraduate degree from Muhlenberg College (conferred in 1975).
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
AVIDITY BIOSCIENCES INC
0.34% | 03-04-2024 | 268 702 ( 0.34% ) | 7 M $ | 31-03-2024 |
STOKE THERAPEUTICS, INC.
0.04% | 01-09-2023 | 17 979 ( 0.04% ) | 242 717 $ | 31-03-2024 |
Actieve functies van Arthur Levin
Bedrijven | Functie | Begin |
---|---|---|
AVIDITY BIOSCIENCES, INC. | Director/Board Member | 23-02-2023 |
STOKE THERAPEUTICS, INC. | Director/Board Member | 01-09-2015 |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Director/Board Member | - |
Eerdere bekende functies van Arthur Levin
Bedrijven | Functie | Einde |
---|---|---|
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Chief Tech/Sci/R&D Officer | 01-01-2014 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Board Member | - |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Corporate Officer/Principal | - |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Arthur Levin
Rochester Christian University | Doctorate Degree |
Muhlenberg College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
AVIDITY BIOSCIENCES, INC. | Health Technology |
STOKE THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Health Technology |